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ABSTRACT
Background: Tumor necrosis factor (TNF)-
blockers are approved for use in several immune-
related conditions, but treatment patterns, 
such as switching between TNF blockers or 
restarting treatment after a gap in therapy, are 
not clearly established. This analysis examined 
TNF blocker treatment patterns within the first 
year after initiating treatment with etanercept, 
adalimumab, or infliximab in patients with 
rheumatoid arthritis, psoriasis, psoriatic arthritis, 
or ankylosing spondylitis.
Methods: Administrative claims data from the 
MarketScan® Commercial Claims and Encounters 
Database (Thomson Reuters, Ann Arbor, MI, 
USA) were analyzed for patients with rheumatoid 
arthritis, psoriasis, psoriatic arthritis, or ankylosing 
spondylitis who were continuously enrolled 
and newly initiated etanercept, adalimumab, or 
infliximab treatment between January 1, 2005 
and July 1, 2009. Persistence (no treatment 
gap ≥45 days), restarting index therapy (after a 
≥45-day treatment gap), switching to a different 
biologic of interest (certolizumab, golimumab, 
ustekinumab, alefacept, abatacept, rituximab, or 
tocilizumab), and stopping (≥45-day treatment 
gap with no restart or switch) were analyzed for 
the first year after the index date.
Results: A total of 8,454 patients had an index 
claim for etanercept (n = 4,224), adalimumab 
(n = 2,941), or infliximab (n = 1,289). Treatment 
patterns in the first year across all four conditions 
combined for etanercept, adalimumab, or 
infliximab, respectively, were: persistence, 42%, 
47%, and 56%; restarting, 25%, 19%, and 12%; 
switching, 13%, 12%, and 13%; and stopping, 
20%, 22%, and 19%. The combined rates of 
either persistence or restarting initial therapy 
after a treatment gap were 67%, 66%, and 68%, 
for etanercept, adalimumab, and infliximab, 
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Two of the studies analyzed rates of switching 
between TNF blockers [10,11], and others focused 
on treatment persistence [12–19]. None of the 
studies analyzed rates of restarting the index 
TNF blocker after a treatment gap. Additionally, 
one study included patients with RA, PsA, or 
AS [19], and others only included patients with 
RA [10–18]. For medications with several shared 
indications, such as etanercept, adalimumab, and 
infliximab, it is important to consider treatment 
patterns across conditions, particularly because 
there is evidence that treatment patterns may 
differ by condition [20]. Additionally, guidelines 
for the use of TNF blockers in the treatment of 
RA [21], PsO [22], PsA [23], and AS [24] do not 
provide clear guidance on restarting treatment or 
switching to a different biologic. The objective 
of this analysis was to examine TNF blocker 
treatment patterns in real-world settings within 
the first year after initiating treatment with 
etanercept, adalimumab, or infliximab in patients 
with RA, PsO, PsA, or AS.
METHODS
Data Source
This retrospective analysis used administrative 
claims data from the MarketScan® Commercial 
Claims and Encounters Database (Thomson 
Reuters, Ann Arbor, MI, USA). This database 
contains the healthcare experience of privately 
insured individuals covered under a variety 
of fee-for-service, fully capitated, and partially 
capitated health plans. The database contains fully 
adjudicated de-identified medical claims (inpatient, 
outpatient, emergency room) and outpatient 
pharmacy claims linked to plan enrollment 
information provided by large employer-sponsored 
health plans from across the United States. There 
are approximately 30 million enrollees per year 
from more than 100 large employers, including 
respectively. Most switches (66–92%) were 
between the three TNF blockers.
Conclusion: In the first year after initiating TNF 
blocker therapy, patients often have a ≥45-day 
treatment gap; however, approximately two-
thirds of patients are either persistent with or 
restart their index therapy in the year following 
TNF blocker initiation.
Keywords :  Adal imumab;  Ankylos ing 
spondylitis; Etanercept; Infliximab; Psoriasis; 
Psoriatic arthritis; Rheumatoid arthritis; TNF 
blocker; Treatment gaps; Treatment patterns
INTRODUCTION
Tumor necrosis factor (TNF)-blockers play 
an important role in the treatment of some 
autoimmune disorders by helping to regulate the 
body’s inflammatory processes and inhibiting 
progressive structural damage in rheumatoid 
arthritis (RA) and psoriatic arthritis (PsA). The 
most widely used TNF blockers are etanercept, 
adalimumab, and infliximab. Each of these TNF 
blockers is indicated for use in adults with the 
following conditions: moderately to severely 
active RA; chronic, moderate-to-severe plaque 
psoriasis (PsO); active PsA; and active ankylosing 
spondylitis (AS). In the controlled setting 
of prospective clinical studies, etanercept, 
adalimumab, and infliximab had comparable 
efficacy for these conditions [1–8]. More than 
20 other clinical studies in patients with RA, 
as reviewed by Scrivo et al. [9], have generally 
shown that switching to a second TNF blocker 
after discontinuation of the initial TNF blocker 
can improve outcomes. However, little is known 
about the frequency with which patients in real-
world settings switch to a second TNF blocker.
Several recent studies have examined 
adherence and persistence rates for etanercept, 
adalimumab, and infliximab treatment [10–19]. 
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infliximab, or a different biologic of interest 
(certolizumab, golimumab, ustekinumab, 
a le facept ,  abatacept ,  r i tuximab,  and 
tocilizumab) any time before its FDA market 
approval for the condition of interest or 
within the pre-index period, or a claim for 
more than one of these biologic treatments 
on the index date. The other biologics were 
not included as index medications because 
an insufficient number of patients initiated 
treatment with these drugs in the study 
period, but patients who received one of these 
biologics after the index date were included 
in analyses of switching to a different biologic 
of interest. Patients were not considered 
to have switched to a different biologic of 
interest if the biologic was not approved for 
that condition: patients with RA, PsA, or AS 
who switched to ustekinumab or alefacept; 
patients with PsO, PsA, or AS who switched 
to tocilizumab, certolizumab, rituximab, or 
abatacept; and patients with PsO who switched 
to golimumab.
Study Measures
Treatment patterns were evaluated for 
360 days after the index date. Persistence with 
the index TNF blocker within the first year 
was defined as no treatment gap ≥45 days 
after the end of estimated clinical benefit 
for that treatment, which was assumed to be 
7 days for each 50 mg syringe of etanercept, 
14 days for each 40 mg syringe of adalimumab, 
and 56 days for each infusion of infliximab. 
Patients with a treatment gap of <45 days 
at the end of the first year were considered 
persistent. Restarting treatment within the 
first year was defined as a ≥45-day treatment 
gap, followed by a subsequent claim for the 
index TNF blocker. Switching biologics was 
defined as a claim for a different biologic of 
administrative claims data on employees, spouses, 
and dependents.
Study Population
Patients with at least one claim for a TNF 
blocker (etanercept, adalimumab, or infliximab) 
between January 1, 2005 and July 1, 2009 
were included in the analysis if they were 
continuously enrolled in a health plan with 
medical and pharmacy benefits for at least 
180 days before and 360 days following initiation 
of TNF blocker treatment. The date of the first 
observed claim for etanercept, adalimumab, 
or infliximab qualified as the index date. The 
pre-index period was defined as the 6-month 
period before the index date. The post-index 
period was the 12-month period following the 
index date. The end date for data included in the 
analysis was June 30, 2010.
Biologic naïve patients were included in 
the analysis if they were 18–64 years of age on 
the index date and had at least one claim with 
a diagnosis code of RA (714.xx), PsO (696.xx, 
except 696.0x), PsA (696.0x), or AS (720.0x) 
in the 180-day pre-index period. Patients with 
International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes for more than one of these 
conditions were not included in this report.
The index date needed to occur within the 
identification period, which began on the first 
month by which all three TNF blockers had been 
approved for use in patients with that condition. 
Thus, the index date for each condition could occur 
on the following dates: RA, between January 1, 
2005 and July 1, 2009; PsO, between February 1, 
2008 and July 1, 2009; PsA, between November 1, 
2005 and July 1, 2009; AS, between 1 August 2006 
and 1 July 2009.
Patients were excluded from the analysis if 
they had a claim for etanercept, adalimumab, 
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interest at any time in the first year after the 
index date. Stopping treatment was defined as 
a ≥45-day treatment gap after the end of the 
estimated clinical benefit, without restarting 
or switching to another biologic of interest in 
the first year after the index date.
Data Analysis
Data were summarized descriptively by 
condition (RA, PsO, PsA, or AS) and initial TNF 
blocker (etanercept, adalimumab, or infliximab). 
Summaries of data at the index date for initial 
TNF blocker included patient characteristics 
(age, sex, geographic location, and plan type) 
and prescribing physician specialty. Analyses 
of treatment patterns included the number 
and percentage of patients who were persistent, 
restarted the initial TNF blocker after a ≥45-day 
treatment gap, switched to a different biologic 
of interest, or stopped the index TNF blocker, 
as defined above. The time to the switch and 
drug to which the patient switched were 
summarized.







Age (years), mean (SD) 48 (11) 49 (11) 51 (10)
Female, n (%) 2,851 (68) 1,988 (68) 946 (73)
Patient geographic region, n (%)
Northeast 449 (11) 269 (9) 137 (11)
Midwest 1,002 (24) 753 (26) 256 (20)
South 2,044 (48) 1,541 (52) 734 (57)
West 706 (17) 364 (12) 158 (12)
Plan type, n (%)
Preferred provider organization 2,540 (60) 1,761 (60) 757 (59)
Health maintenance organization 669 (16) 480 (16) 221 (17)
Point of service 526 (12) 346 (12) 146 (11)
Indemnity plan 287 (7) 216 (7) 92 (7)
Other 105 (3) 84 (3) 43 (3)
Unknown 97 (2) 54 (2) 30 (2)
Prescribing physician specialty,a n (%)
Rheumatology 1,332 (32) 958 (33) 817 (63)
Internal medicine 987 (23) 723 (25) 258 (20)
General practitioner 382 (9) 258 (9) 34 (3)
Dermatology 322 (8) 182 (6) 5 (0)
Other 1,134 (27) 785 (27) 163 (13)
Unknown 67 (2) 35 (1) 12 (1)
a Prescribing physician specialty was defined using the claim nearest the index claim. The “other” category includes physician 
not elsewhere classified. If a physician practiced in a multi-physician specialty then the claim was often classified as not 
elsewhere classified and hence was classified as “other” in this analysis. The patients in the “other” category may have seen a 
rheumatologist at another time, just not during the visit closest to the index event
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RESULTS
The study criteria were met in 8,454 patients who 
newly initiated TNF blocker treatment in the study 
period. Among patients with RA, PsO, PsA, and AS, 
the mean (SD) age at baseline was 50 (10), 44 (11), 
48 (10), and 43 (12) years, respectively, and 76%, 
46%, 50%, and 40% of patients, respectively, were 
women. The initial TNF blocker treatment was 
etanercept in 4,224 (50%) patients, adalimumab 
in 2,941 (35%) patients, and infliximab in 1,289 
(15%) patients. Baseline demographic and clinical 
characteristics were similar between the three 
treatment groups (Table 1); in the etanercept, 
adalimumab, and infliximab groups, respectively, 
mean (SD) age was 48 (11), 49 (11), and 51 
(10) years, and 68%, 68%, and 73% of patients 
were women.
Treatment patterns for all patients combined 
are summarized in Fig. 1. For all conditions 
combined, treatment patterns in the first year after 
starting etanercept, adalimumab, or infliximab 
treatment, respectively, were: persistence, 42%, 
47%, and 56%; restarting initial TNF blocker after 
a ≥45-day treatment gap, 25%, 19%, and 12%; 
switch to a different biologic of interest, 13%, 
12%, and 13%; and stop (≥45-day treatment gap 
with no restart or switch), 20%, 22%, and 19%. 
Thus, the combined rates of either persistence 
or restarting after a treatment gap were 67%, 
66%, and 68% for etanercept, adalimumab, and 
infliximab, respectively.
Most patients who switched from the index 
TNF blocker to a different biologic of interest 
in the first year switched to one of the other 
index TNF inhibitors (Fig. 1), and the most 
common switches were between etanercept 
and adalimumab. Of the patients who switched 
from etanercept to a different biologic, 73% 
switched to adalimumab, 19% to infliximab, 
and 8% to another biologic of interest. Of the 
patients who switched from adalimumab to a 
different biologic, 62% switched to etanercept, 
25% to infliximab, and 13% to another biologic 
of interest. Of the patients who switched from 
infliximab to a different biologic, 31% switched 
to etanercept, 36% to adalimumab, and 34% to 
another biologic of interest.
Fig. 1  Treatment patterns in the first year for newly 
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Table 2  Treatment patterns in the first year, by condition
Treatment pattern in the first year No. (%) of patients
Etanercept Adalimumab Infliximab
Rheumatoid arthritis (n = 2,933) (n = 2,094) (n = 1,099)
Persistent use (no switch or ≥45-day gap)a 1,317 (45) 1,003 (48) 624 (57)
Restart (after ≥45-day gap) 675 (23) 387 (18) 122 (11)
Switch to 446 (15) 294 (14) 146 (13)
 Etanercept – 181 (9) 42 (4)
 Adalimumab 308 (11) – 52 (5)
 Infliximab 95 (3) 69 (3) –
 Other biologic of interestb 43 (1) 44 (2) 52 (5)
Stop (≥45-day gap, no restart or switch) 495 (17) 410 (20) 207 (19)
Psoriasis (n = 545) (n = 318) (n = 11)
Persistent use (no switch or ≥45-day gap)a 121 (22) 105 (33) 4 (36)
Restart (after ≥45-day gap) 176 (32) 76 (24) 1 (9)
Switch to 39 (7) 18 (6) 1 (9)
 Etanercept – 9 (3) 0 (0)
 Adalimumab 35 (6) – 1 (9)
 Infliximab 2 (<1) 5 (2) –
 Other biologic of interestb 2 (<1) 4 (1) 0 (0)
Stop (≥45-day gap, no restart or switch) 209 (38) 119 (37) 5 (45)
Psoriatic arthritis (n = 597) (n = 426) (n = 133)
Persistent use (no switch or ≥45-day gap)a 281 (47) 225 (53) 75 (56)
Restart (after ≥45-day gap) 172 (29) 73 (17) 23 (17)
Switch to 62 (10) 46 (11) 13 (10)
 Etanercept – 33 (8) 5 (4)
 Adalimumab 52 (9) – 4 (3)
 Infliximab 9 (2) 13 (3) –
 Other biologic of interestb 1 (<1) 0 (0) 4 (3)
Stop (≥45-day gap, no restart or switch) 82 (14) 82 (19) 22 (17)
Ankylosing spondylitis (n = 149) (n = 103) (n = 46)
Persistent use (no switch or ≥45-day gap)a 71 (48) 35 (34) 19 (41)
Restart (after ≥45-day gap) 24 (16) 21 (20) 7 (15)
Switch to 12 (8) 11 (11) 6 (13)
 Etanercept – 6 (6) 4 (9)
 Adalimumab 12 (8) –  2 (4)
 Infliximab 0 (0) 3 (3) –
 Other biologic of interestb 0 (0) 0 (0) 0 (0)
Stop (≥45-day gap, no restart or switch) 42 (28) 36 (35) 14 (30)
a Patients with a treatment gap of <45 days at the end of the first year were counted in this row
b Certolizumab, golimumab, ustekinumab, alefacept, tocilizumab, abatacept, or rituximab
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Treatment patterns are summarized 
by treatment and condition in Table 2. 
Patients with RA comprised 72% of the study 
population, and treatment patterns by TNF 
blocker treatment group in these patients 
were generally consistent with those of the 
overall study population. Among patients with 
RA, treatment patterns in the first year after 
starting etanercept, adalimumab, or infliximab 
treatment, respectively, were: persistence, 45%, 
48%, 57%; restarting initial TNF blocker after 
a ≥45-day treatment gap, 23%, 18%, and 11%; 
switch to a different biologic of interest, 15%, 
14%, and 13%; and stop (≥45-day treatment gap 
with no restart or switch), 17%, 20%, and 19%. 
Thus, the combined rates of either persistence 
or restarting initial TNF blocker treatment after 
a treatment gap among patients with RA were 
68%, 66%, and 68% for etanercept, adalimumab, 
and infliximab, respectively.
Table 3  Time from index date to restart of initial TNF blocker or switch to a different biologic of interest
Mean (± SD) time, days; no. of patients
Etanercept Adalimumab Infliximab
Rheumatoid arthritis (n = 2,933) (n = 2,094) (n = 1,099)
Time to restart 219 ± 79; n = 675 223 ± 82; n = 387 240 ± 77; n = 122
Time to switch to
 Etanercept – 184 ± 90; n = 181 207 ± 96; n = 42
 Adalimumab 183 ± 91; n = 308 – 170 ± 85; n = 52
 Infliximab 174 ± 88; n = 95 178 ± 78; n = 69 –
Psoriasis (n = 545) (n = 318) (n = 11)
Time to restart 226 ± 80; n = 176 230 ± 83; n = 76 9; n = 1
Time to switch to
 Etanercept – 137 ± 84; n = 9 NA; n = 0
 Adalimumab 208 ± 96; n = 35 – 342; n = 1
 Infliximab 344 ± 22; n = 2 130 ± 130; n = 5 –
Psoriatic arthritis (n = 597) (n = 426) (n = 133)
Time to restart 230 ± 81; n = 172 233 ± 85; n = 73 263 ± 75; n = 23
Time to switch to
 Etanercept – 213 ± 83; n = 33 123 ± 50; n = 5
 Adalimumab 192 ± 87; n = 52 – 147 ± 112; n = 4
 Infliximab 133 ± 47; n = 9 197 ± 91; n = 13 –
Ankylosing spondylitis (n = 149) (n = 103) (n = 46)
Time to restart 206 ± 92; n = 24 211 ± 84; n = 21 261 ± 57; n = 7
Time to switch to
 Etanercept – 153 ± 72; n = 6 169 ± 128; n = 4
 Adalimumab 175 ± 56; n = 12 – 67 ± 4; n = 2
 Infliximab NA; n = 0 173 ± 75; n = 3 –
n values are provided for the full group of patients with that condition and index TNF blocker; mean (± SD) values were 
calculated among the patients who restarted or switched
NA not applicable (no patients switched), TNF tumor necrosis factor
Adv Ther (2012)  29(8):664–674. 671
Among patients with PsO (Table 2), treatment 
patterns in the first year after starting etanercept, 
adalimumab, or infliximab treatment, 
respectively, were: persistence, 22%, 33%, 36%; 
restarting initial TNF blocker after a ≥45-day 
treatment gap, 32%, 24%, and 9%; switch to a 
different biologic of interest, 7%, 6%, and 9%; 
and stop (≥45-day treatment gap with no restart 
or switch), 38%, 37%, and 45%. Thus, combined 
rates of either persistence or restarting after a 
treatment gap among patients with PsO were 
54%, 57%, and 45% for etanercept, adalimumab, 
and infliximab, respectively.
Among patients with PsA (Table 2), treatment 
patterns in the first year after starting etanercept, 
adalimumab, or infliximab treatment, 
respectively, were: persistence, 47%, 53%, 56%; 
restarting initial TNF blocker after a ≥45-day 
treatment gap, 29%, 17%, and 17%; switch to 
a different biologic of interest, 10%, 11%, and 
10%; and stop (≥45-day treatment gap with no 
restart or switch), 14%, 19%, and 17%. Thus, the 
combined rates of either persistence or restarting 
after a treatment gap among patients with 
PsA were 76%, 70%, and 73% for etanercept, 
adalimumab, and infliximab, respectively.
Among patients with AS (Table 2), treatment 
patterns in the first year after starting etanercept, 
adalimumab, or infliximab treatment, 
respectively, were: persistence, 48%, 34%, 41%; 
restarting initial TNF blocker after a ≥45-day 
treatment gap, 16%, 20%, and 15%; switch to a 
different biologic of interest, 8%, 11%, and 13%; 
and stop (≥45-day treatment gap with no restart 
or switch), 28%, 35%, and 30%. Thus, combined 
rates of either persistence or restarting after 
a treatment gap among patients with AS were 
64%, 54%, and 56% for etanercept, adalimumab, 
and infliximab, respectively.
Table 3 summarizes the time from the 
index date to restarting the index TNF blocker 
or switching to a different TNF blocker. 
Among patients with RA, the mean (SD) time to 
restarting the index TNF blocker was 219 (79) days 
for etanercept, 223 (82) days for adalimumab, 
and 240 (77) days for infliximab. Similar values 
were seen between treatment groups for the time 
to restarting the index TNF blocker in patients 
with PsO, PsA, or AS; the only exception was the 
time to restart infliximab in PsO, but this value 
was based on only one patient who restarted 
treatment. Mean times to switching from the 
index TNF blocker to one of the other two index-
eligible TNF blockers ranged from 170 to 207 days 
among patients with RA, from 137 to 342 days 
among patients with PsO, from 123 to 213 days 
among patients with PsA, and from 67 to 
175 days among patients with AS.
DISCUSSION
In this analysis of patients with RA, PsO, PsA, 
or AS initiating a TNF blocker from real-world 
settings in the United States, etanercept was the 
most commonly prescribed initial TNF blocker 
(50%), followed by adalimumab (35%) and 
infliximab (15%). In the first year after starting 
TNF blocker treatment, approximately two-
thirds of patients either were persistent with 
their index TNF blocker, or restarted treatment 
with their index TNF blocker after a ≥45-day 
treatment gap, regardless of the index TNF 
blocker (67%, 66%, and 68% for etanercept, 
adalimumab, and infliximab, respectively). The 
other patients either switched to a different 
biologic (13%) or they stopped TNF blocker 
treatment without restarting or switching to a 
different TNF blocker (20%).
A key aspect of this analysis was the inclusion 
of patients with one of four conditions in a large, 
nationwide database. This approach enhanced 
the generalizability of the results to formulary 
decisions and payers who are interested in 
treatment patterns after the initiation of TNF 
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blocker treatment among patients with a 
variety of conditions. It also provided insight 
into treatment patterns for each of the specific 
conditions. Although the rates varied by 
condition, they were similar between etanercept, 
adalimumab, and infliximab within each 
condition and across all conditions combined.
A previous analysis of 6,739 patients with RA 
in a British registry reported that over a mean 
of 15 months, 856 (13%) patients switched 
to a second agent, and 73% of these patients 
remained on the second agent at the end of 
follow-up [10]. A recent retrospective analysis 
of a commercial database evaluated dosing and 
discontinuation rates for TNF blocker treatment 
in 3,217 patients with RA [11]. For the first TNF 
blocker treatment, the percentage of patients 
who stopped treatment (defined as a ≥60-day 
treatment gap or a switch to non-index biologic 
treatment) was 50% for etanercept, 53% for 
adalimumab, and 40% for infliximab [11]. 
However, because “stopping treatment” in that 
study included all patients with a treatment 
gap of ≥60 days, it is likely that many of the 
patients subsequently restarted their index TNF 
blocker treatment. The other previous studies 
comparing treatment patterns for TNF blockers 
focused on compliance and persistence and were 
either restricted to patients with RA [10–18] 
or did not include patients with PsO [19]. A 
literature search identified no previous studies 
that evaluated treatment patterns across all four 
conditions or included restarting the index TNF 
blocker after a treatment gap.
A possible limitation of this analysis was 
that it used claims data, which do not capture 
the reason for discontinuation of TNF blocker 
treatment. Thus, it is unknown whether factors 
such as physician beliefs or patient beliefs, 
tolerability, or efficacy contributed to gaps in 
treatment, stopping treatment, or switching to 
a different biologic of interest. Likewise, this 
analysis required 12 months of continuous 
medical and pharmacy enrollment following 
treatment initiation, effectively limiting the 
analysis to patients with health insurance for 
one year following TNF blocker initiation. 
As a result, loss of health insurance could 
not be evaluated as a potential reason for 
discontinuation. This study was designed to 
include data for commercial health coverage 
only, and may not be generalizable to Medicare 
or other noncommercial populations.
In summary, across four different conditions, 
patients often have treatment gaps in the first 
year after initiating TNF blocker treatment 
with etanercept, adalimumab, or infliximab. 
Thus, when looking at treatment patterns, 
it is important to consider the contribution 
of restarting index therapy after a treatment 
gap. Approximately two-thirds of patients 
are persistent or restart index therapy after 
a treatment gap and the percentages are 
similar between etanercept, adalimumab, and 
infliximab, both across the four conditions and 
within each condition. When patients switch to 
another biologic treatment, they usually switch 
to one of these three TNF blockers, rather than 
to other biologics. Further research is needed 
to assess whether treatment gaps influence 
effectiveness.
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